Early Childhood Educators’ Perceptions of Using Conscious Discipline to Promote Executive Function Development in Preschool Students: A Case Study

This applied dissertation was designed to explore teacher perceptions of the use of Conscious Discipline in the classroom to promote desirable behaviors and influence the development of EF skills in children. Using self-assessment surveys, qualitative interviews, and direct observations, the researcher explored teacher perceptions of the use of Conscious Discipline as a behavioral management system to develop EF in preschool children. Conscious Discipline is an emotional intelligence behavior-management system that promotes desirable behaviors in children, embracing those skills found in the prefrontal lobes of the brain, which control the mechanism for self-regulation and problem-solving skills. Conscious Discipline promotes the development of self-regulation in preschool students, a key element in developing EF. The goal of this study was to add to the research literature on the usefulness and importance of using Conscious Discipline to promote EF in children at an early age. Participants were 5 teachers in a private preschool center in South Florida serviced by the state college’s institute in early care. Overall, four themes emerged. Teachers learned the importance of the development of self-regulation in students. Internalization of the teacher’s journey in Conscious Discipline afforded implementation. Teachers increased their awareness of self and lifelong skills. Reaching executive state in Conscious Discipline affords academic successes. An implication is the importance of professional development in brain-based Conscious Development to help preschool teachers develop EF in their students

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016) : part two

Background The immunological escape of tumors represents one of the main ob- stacles to the treatment of malignancies. The blockade of PD-1 or CTLA-4 receptors represented a milestone in the history of immunotherapy. However, immune checkpoint inhibitors seem to be effective in specific cohorts of patients. It has been proposed that their efficacy relies on the presence of an immunological response. Thus, we hypothesized that disruption of the PD-L1/PD-1 axis would synergize with our oncolytic vaccine platform PeptiCRAd. Methods We used murine B16OVA in vivo tumor models and flow cytometry analysis to investigate the immunological background. Results First, we found that high-burden B16OVA tumors were refractory to combination immunotherapy. However, with a more aggressive schedule, tumors with a lower burden were more susceptible to the combination of PeptiCRAd and PD-L1 blockade. The therapy signifi- cantly increased the median survival of mice (Fig. 7). Interestingly, the reduced growth of contralaterally injected B16F10 cells sug- gested the presence of a long lasting immunological memory also against non-targeted antigens. Concerning the functional state of tumor infiltrating lymphocytes (TILs), we found that all the immune therapies would enhance the percentage of activated (PD-1pos TIM- 3neg) T lymphocytes and reduce the amount of exhausted (PD-1pos TIM-3pos) cells compared to placebo. As expected, we found that PeptiCRAd monotherapy could increase the number of antigen spe- cific CD8+ T cells compared to other treatments. However, only the combination with PD-L1 blockade could significantly increase the ra- tio between activated and exhausted pentamer positive cells (p= 0.0058), suggesting that by disrupting the PD-1/PD-L1 axis we could decrease the amount of dysfunctional antigen specific T cells. We ob- served that the anatomical location deeply influenced the state of CD4+ and CD8+ T lymphocytes. In fact, TIM-3 expression was in- creased by 2 fold on TILs compared to splenic and lymphoid T cells. In the CD8+ compartment, the expression of PD-1 on the surface seemed to be restricted to the tumor micro-environment, while CD4 + T cells had a high expression of PD-1 also in lymphoid organs. Interestingly, we found that the levels of PD-1 were significantly higher on CD8+ T cells than on CD4+ T cells into the tumor micro- environment (p < 0.0001). Conclusions In conclusion, we demonstrated that the efficacy of immune check- point inhibitors might be strongly enhanced by their combination with cancer vaccines. PeptiCRAd was able to increase the number of antigen-specific T cells and PD-L1 blockade prevented their exhaus- tion, resulting in long-lasting immunological memory and increased median survival